Announced details
NK/T-cell lymphoma, peripheral T-cell lymphoma, combination with immunotherapy, and hematologic and solid tumors
Collaborative research relationship. シンバイオ製薬 obtained the global license for BCV in September 2019.
National Cancer Centre Singapore (NCCS). Location, capital and year established: Not disclosed. The principal investigator is Dr. Jason Chan, a senior consultant in NCCS's Division of Medical Oncology and an associate professor at Duke-NUS Medical School.
The company explained that publication of the paper could accelerate development in the oncology field and help establish it as a new pillar of its growth strategy. The specific impact on financial results is Not disclosed.
The company does not address Contract Value / Offering price.
Paper published in BMC Medicine, “Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma.” DOI: 10.1186/s12916-026-04680-8
| Item | Details |
|---|---|
| Names of Products / Services Covered | IV BCV (injectable brincidofovir) |
| Counterparty | National Cancer Centre Singapore (NCCS) |
| Counterparty overview | National Cancer Centre Singapore (NCCS). Location, capital and year established: Not disclosed. The principal investigator is Dr. Jason Chan, a senior consultant in NCCS's Division of Medical Oncology and an associate professor at Duke-NUS Medical School. |
| Relationship with the Company | Collaborative research relationship. シンバイオ製薬 obtained the global license for BCV in September 2019. |
| Applicable area | NK/T-cell lymphoma, peripheral T-cell lymphoma, combination with immunotherapy, and hematologic and solid tumors |
| Impact on Business Performance | The company explained that publication of the paper could accelerate development in the oncology field and help establish it as a new pillar of its growth strategy. The specific impact on financial results is Not disclosed. |
| Source | Paper published in BMC Medicine, “Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma.” DOI: 10.1186/s12916-026-04680-8 |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company disclosed the results of a collaborative study with the National Cancer Centre Singapore (NCCS). The company explained that these scientific findings could accelerate development in the oncology field and lead to a new pillar of its growth strategy.